2016
Improved i.p. drug delivery with bioadhesive nanoparticles
Deng Y, Yang F, Cocco E, Song E, Zhang J, Cui J, Mohideen M, Bellone S, Santin AD, Saltzman WM. Improved i.p. drug delivery with bioadhesive nanoparticles. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 11453-11458. PMID: 27663731, PMCID: PMC5068292, DOI: 10.1073/pnas.1523141113.Peer-Reviewed Original ResearchConceptsChemotherapeutic agentsUterine serous carcinoma patientsBioadhesive nanoparticlesAdministration of chemotherapySerous carcinoma patientsPotent chemotherapeutic agentPeritoneal carcinomatosisCarcinoma patientsPeritoneal spaceAbdominal cavityLow systemic toxicityLymphatic drainageTherapeutic efficacyMesothelial cellsHigh therapeutic efficacySystemic toxicityFast clearanceEfficacy of nanoparticlesEfficacyFree EBBiodegradable nanoparticlesNanoparticlesDrug deliveryCarcinomatosisChemotherapy
1996
Development and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules
Santin A, Ioli G, Hiserodt J, Manetta A, Pecorelli S, DiSaia P, Granger G. Development and characterization of an interleukin-2–transduced human ovarian carcinoma tumor vaccine not expressing major histocompatibility complex molecules. American Journal Of Obstetrics And Gynecology 1996, 174: 633-640. PMID: 8623798, DOI: 10.1016/s0002-9378(96)70441-6.Peer-Reviewed Original ResearchConceptsIL-2Interleukin-2Ovarian carcinoma cellsOvarian cancerAllogeneic peripheral blood lymphocytesAdvanced epithelial ovarian cancerBALB/c nude miceChromium-51 release assaysMajor histocompatibility complex class IAdvance ovarian cancerCarcinoma cellsHistocompatibility complex class IEpithelial ovarian cancerMajor histocompatibility complex moleculesPeripheral blood lymphocytesHuman ovarian carcinoma cell linesHuman ovarian carcinoma cellsOvarian carcinoma cell linesComplex class ICytokine interleukin-2Long-term cytotoxicHistocompatibility complex moleculesMonths of studyUCI-107Tumor vaccines